polaris retatrutide news october 2025 Demand for Unapproved Weight-Loss Drug Surges on Social Media What is Retatrutide & When
Description
Retention of glucagon function is required to achieve such an advantage over GLP-1 monotherapy
In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)
Dallas-based Smoothie King debuted its GLP-1 Support Menu on Tuesday for those who are using GLP-1 agonists to help them achieve their weight loss goals.
The airball comes as Novo scrambles to regain a majority share of the GLP-1 market.
PlexusDx explains the actual risk profile and how personalized compounded semaglutide therapy prioritizes your cardiovascular safety
